FDA approves Decnupaz (pivekimab sunirine) for adult blastic plasmacytoid dendritic cell neoplasm

The U.S. Food and Drug Administration has approved DECNUPAZ (pivekimab sunirine-pvzy) for the rare hematologic malignancy blastic plasmacytoid dendritic cell neoplasm (BPDCN). Multiple sources describe BPDCN as an ultra-rare and aggressive blood cancer with limited treatment options. The FDA approval specifies use in adult patients. One report notes that the drug is an antibody-drug conjugate, and that the approval covers outpatient use, including initiation in that setting. PR Newswire also states that DECNUPAZ is the first and only approved antibody-drug conjugate for BPDCN and that it is AbbVie’s first approved antibody-drug conjugate for a blood cancer. Together, the reporting focuses on the approval status, the targeted cancer indication, and the specified population and treatment setting, without adding additional comparative claims about other therapies.